OncoMatch/Clinical Trials/NCT06615752
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Is NCT06615752 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies green tea and quercetin + docetaxel for metastatic castration-resistant prostate cancer (mcrpc).
Treatment: green tea and quercetin + docetaxel — The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: medical castration (luteinizing hormone-releasing hormone analogue) — concurrent
History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
Must have received: androgen receptor inhibitor (enzalutamide, apalutamide, darolutamide, abiraterone acetate) — concurrent
Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
Cannot have received: chemotherapy
Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
Cannot have received: radiation therapy
Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
Lab requirements
Blood counts
absolute neutrophil count (ANC) more than 1500 cells/mm³, platelet count more than 100,000 cells/mm³
Kidney function
serum creatinine level within normal limits
Liver function
total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN
Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³) Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN) Adequate renal function (serum creatinine level within normal limits)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Charles R. Drew University of Medicine and Science · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify